Market Overview

UPDATE: Piper Jaffray Initiates Galena Biopharma at Overweight on ImmunoRx Potential

Related GALE
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., As President And CEO
Morning Market Losers

Piper Jaffray initiated coverage on Galena Biopharma (NASDAQ: GALE) with an Overweight rating and a $2.50 price target.

Piper Jaffray commented, "Galena is a cancer immunotherapy company that is developing NeuVax, which could be a new blockbuster breast cancer adjuvant therapy. Galena should complete enrollment of the Phase III PRESENT trial this summer with 36-month Disease Free Survival (DFS) data in mid-2016. Galena is also developing a Folate Binding Protein E39 (FBP-E39) targeted vaccine in a Phase I/II ovarian and endometrial cancer trial with preliminary data at ASCO in June. We look for clinical progress and potential partnerships to drive shareholder value in 2013. Galena recently raised $24 million, which should fund the company into 2014."

Galena Biopharma closed at $1.55 on Friday.

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (GALE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters